IP Library Granted Patent US 10,953,095
Granted Patent B2
US 10,953,095 · App. 16/593,661 · Granted Mar 23, 2021

Lipid compositions

Inventors: Muthiah Manoharan (Cambridge, MA); Kallanthottathil G. Rajeev (Cambridge, MA); Muthusamy Jayaraman (Cambridge, MA); David Butler (Medford, MA); Michael E. Jung (Cambridge, MA)
Assignee: ARBUTUS BIOPHARMA CORPORATION
A61K47/22A61K9/1272C07D295/13C12N15/113C12N15/1137C12N2310/14Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,953,095
App. No.
16/593,661
Granted
Mar 23, 2021
Kind
B2
Abstract

Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is Also disclosed are methods of producing the cationic lipid of formula (I).

Claims (31)

1. A lipid of formula (I):

or a salt thereof, wherein,

each X a and X b , for each occurrence, is independently C 1-6 alkylene;

1, 2, 3, 4, or 5;

A for each occurrence is NR 2 or a cyclic moiety optionally substituted with 1-3 R;

B is NR or a cyclic moiety optionally substituted with 1-2 R;

each R is independently H, alkyl,

provided that at least one R is

R 1 , for each occurrence, is independently H, R 3 ,

R 2 , for each occurrence, is independently, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl;

R 3 , for each occurrence, is independently, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl;

Y, for each occurrence, is O;

R 4 , for each occurrence is independently H alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl.

2. The lipid of claim 1 , wherein n is 1 or 2.

3. The lipid of claim 1 , wherein A for each occurrence is NR 2 .

4. The lipid of claim 1 , wherein B is a cyclic moiety.

5. The lipid of claim 1 , wherein B is a nitrogen containing cyclic moiety.

6. The lipid of claim 1 , wherein B is piperidinyl or piperizinyl moiety.

7. The lipid of claim 1 , wherein each R is independently

8. The lipid of claim 1 , wherein R 1 , for each occurrence, is H.

9. The lipid of claim 1 , wherein R 2 , for each occurrence, is independently alkyl.

10. The lipid of claim 1 , wherein R 2 , for each occurrence, is independently, alkenyl.

11. The lipid of claim 1 , wherein n is 1 or 2; A is NR 2 ; B is NR or a cyclic moiety; R 1 is H; R 2 is independently alkyl or alkenyl; Y is O; and R is

12. The lipid of claim 1 , wherein n is 1; A is NR 2 ; B is a cyclic moiety; R 1 is H; R 2 is independently alkyl or alkenyl; Y is O; and R is

13. A composition, the composition comprising a sterol, a neutral lipid, a PEG or a PEG-modified lipid, and a lipid as described in claim 1 .

14. The composition of claim 13 , wherein the sterol is cholesterol.

15. The composition of claim 13 , wherein the PEG or PEG-modified lipid is a PEG-modified lipid.

16. The composition of claim 13 , wherein the composition is a liposome.

17. The composition of claim 13 , further comprising a nucleic acid agent.

18. The composition of claim 17 , wherein the nucleic acid agent is siRNA.

19. The composition of claim 17 , wherein the nucleic acid agent is mRNA.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2021
From: MANOHARAN, MUTHIAH; RAJEEV, KALLANTHOTTATHIL G.; JAYARAMAN, MUTHUSAMY; BUTLER, DAVID; JUNG, MICHAEL E.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 054882/0411 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2021
From: ALNYLAM PHARMACEUTICALS, INC.
To: TEKMIRA PHARMACEUTICALS CORPORATION
Reel/Frame 054882/0455 →
CHANGE OF NAME Recorded Jan 11, 2021
From: TEKMIRA PHARMACEUTICALS CORPORATION
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 054882/0478 →
MERGER AND CHANGE OF NAME Recorded Jan 11, 2021
From: PROTIVA BIOTHERAPEUTICS INC.; ARBUTUS BIOPHARMA CORPORATION
To: ARBUTUS BIOPHARMA CORPORATION
Reel/Frame 054960/0746 →
Continuity (6)
Continuation 15594244 · May 12, 2017
Continuation 14508805 · Oct 7, 2014
Continuation 13318600
Provisional Application 61299291 · Jan 28, 2010
Provisional Application 61175770 · May 5, 2009
Related Publication 20200138955A1 · May 7, 2020